SELECTOR: Selective mRNA-LNP Engineering for Cost-Effective in situ CAR T-cell Programming
Kernal Biologics, Inc. in Cambridge, Mass. intends to use a novel lipid nanoparticle-based platform to treat multiple sclerosis and blood cancers.
Kernal Biologics, Inc. in Cambridge, Mass. intends to use a novel lipid nanoparticle-based platform to treat multiple sclerosis and blood cancers.